drug
tralokinumab
Marketedupdated 5mo agoby LEO Pharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(7)
approval · 7
Dec 27, 2021
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Jul 27, 2022
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Jun 2, 2023
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Dec 14, 2023
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Jun 12, 2024
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Dec 12, 2025
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Dec 17, 2025
approval
ADBRY (TRALOKINUMAB) — FDA approval
tralokinumab
→
Trials studying tralokinumab
- phase2Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
- phase1A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
- phase3A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- —Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
- phase3A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
- phase3Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
- phase3Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
- phase3Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
News(4)
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugThis is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.biospace · 1mo ago
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 1mo ago
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that